Patco, Both Org-24448 and Org-26576 are Cortex-developed compounds, and part of the Cortex-Organon partnership agreement. That partnership was for Schizophrenia and Depression. Org-24448 went through a Phase 2 in Schizo, but for Depression, Schering has apparently replaced Org-24448 in favor of Org-26576.
As for ADHD, that indication wasn't part of the original Cortex-Organon partnership, but since Cortex doesn't have a broad use patent for ADHD (due to prior art), Schering can pursue the indication. At minimum, Cortex would be due the royalty/milestone rate that was in the original Cortex-Organon partnership, since the compound (Org-26576) was part of that deal, even though the indication (ADHD) wasn't.
Cortex has some additional leverage, since Org-26576 is an older compound (patent life similar to CX-717, which is approx 2017, plus perhaps 1-2 years), and Cortex now has the newer Ampakines like CX-1739 (more potent, patent life to 2028).
Schering will have its Org-26576 ADHD Phase 2 results in Q1-09. Cortex plans to take CX-1739 into an ADHD Phase 2 in H2-09. If Schering want's to continue in ADHD, they will likely be interested in partnering for CX-1739. Schering really can't afford to leave CX-1739 out there, since Cortex could just partner CX-1739/ADHD with another pharma, and CX-1739 is the more potent compound, with a full 20 year patent life.
Market Data 
Markets 
AI
